Biomarker panel for detection of chronic obstructive pulmonary disease, method and device thereof
This technology provides an assay kit for detection of COPD using a metabolite biomarker panel measured in metabolite extracts from lung tissue. The single granted claim requires at least one probe for quantification and at least two biomarkers selected from 16 defined metabolites. The claimed signature includes increased Prostaglandin D2, Palmitoylcarnitine, Ornithine, Caprolactam, Hypoxanthine, Xanthine, Nicotinamide and Fumaric acid, or decreased Cholic acid, Oleic acid, 12-Hydroxylauric acid, L-Glutathione oxidized, (+/-)14(15)-DiHET, (+/-)8(9)-DiHET, Adrenic acid and 2-Arachidonoyl glycerol. The supporting preclinical study used a cigarette-smoke-exposed Wistar rat model. Lung tissues were assessed by ATRFTIR and mass-spectrometry-based global and targeted metabolomics. PCA of global metabolomics showed distinct separation of cigarette-smoke COPD and normal groups, and targeted metabolomics demonstrated significant differences for Ornithine, Caprolactam, Hypoxanthine, Xanthine and Nicotinamide.
COPD is generally evaluated using lung-function and imaging approaches, while early disease can be difficult to characterize. Tissue-level metabolic changes offer a complementary biological readout of smokeinduced lung injury. The technology addresses the need for a defined, multi-metabolite signature that can be incorporated into a standardized assay format for COPD-related tissue analysis.
- Granted assay-kit claim based on lung-tissue metabolite extracts.
- Uses at least two biomarkers selected from a defined panel of 16 metabolites, reducing dependence on a single analyte.
- Specifies directional COPD-associated changes: eight metabolites increased and eight decreased relative to normal controls.
- Developed using complementary ATR-FTIR, global LC-MS metabolomics and targeted PRM metabolomics.
- The preclinical study was conducted under OECD GLP principles and ISO 17025:2017 at APT Research Foundation.
- Global metabolomics PCA showed distinct separation between cigarette-smoke COPD and normal lung tissue, while targeted metabolomics confirmed significant differences in selected metabolites.
No physical packaged assay-kit prototype is documented in the granted specification. The demonstrated prototype-equivalent at this stage is the laboratory analytical workflow: lung-tissue metabolite extraction followed by global and targeted LC-MS analysis and defined biomarker interpretation. Although the original specification also describes sensor/device embodiments, the granted claim is limited to the assay kit; therefore commercialization materials should not present a physical sensor as a granted product claim.
The invention establishes a defined metabolic signature of cigarette-smoke-induced COPD in lung tissue and may help advance mechanistic, translational and tissue-based biomarker research. It could support development of standardized assays for research or pathology settings and may provide a basis for future translation of COPD-associated metabolite signatures. Because the present evidence is preclinical and tissue-based, human diagnostic or screening benefit should not yet be claimed.
- COPD and smoke-exposure biomarker research
- Lung-tissue metabolomics and pathology research
- LC-MS / targeted-metabolomics assay development
- Translational respiratory-disease studies
- IVD and tissue-assay R&D
- Pharmaceutical biomarker and mechanism-of-action studies
- Preclinical model characterization